Nikola’s stock falls after bankruptcy rumors surface, and a significant decline in revenue amid recent ongoing fraud allegations. read more

Dr. Reddy’s Q3 FY2025 revenue reached $977 million, up 16%, with $165M net income. Growth fueled by NRT portfolio and global generics expansion. read more

Latest Ratings for GPOR Date Firm Action From To Oct 2021 Truist Securities Maintains Buy Sep 2021 JP Morgan Upgrades Underweight Neutral Jul 2021 Truist Securities Maintains Buy View More Analyst Ratings for GPOR View the Latest Analyst Ratings read more

Latest Ratings for ZBH Date Firm Action From To Mar 2022 Loop Capital Downgrades Buy Hold Feb 2022 Loop Capital Maintains Buy Feb 2022 RBC Capital Maintains Sector Perform View More Analyst Ratings for ZBH View the Latest Analyst Ratings read more

Latest Ratings for CRL Date Firm Action From To Feb 2022 Citigroup Upgrades Neutral Buy Feb 2022 Morgan Stanley Maintains Overweight Feb 2022 Keybanc Maintains Overweight View More Analyst Ratings for CRL View the Latest Analyst Ratings read more

Latest Ratings for FANG Date Firm Action From To Mar 2022 Scotiabank Upgrades Sector Perform Sector Outperform Mar 2022 B of A Securities Downgrades Buy Neutral Mar 2022 Raymond James Maintains Strong Buy View More Analyst Ratings for FANG View the Latest Analyst Ratings read more

Latest Ratings for WTFC Date Firm Action From To Mar 2022 Janney Montgomery Scott Upgrades Neutral Buy Jan 2022 Raymond James Maintains Strong Buy Nov 2021 Raymond James Maintains Strong Buy View More Analyst Ratings for WTFC View the Latest Analyst Ratings read more

read more

read more

read more